000 00846 a2200253 4500
005 20250517114307.0
264 0 _c20180305
008 201803s 0 0 eng d
022 _a1474-5488
024 7 _a10.1016/S1470-2045(16)30409-0
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aHassel, Jessica C
245 0 0 _aIpilimumab plus nivolumab for advanced melanoma.
_h[electronic resource]
260 _bThe Lancet. Oncology
_c11 2016
300 _a1471-1472 p.
_bdigital
500 _aPublication Type: Journal Article; Comment
650 0 4 _aAntibodies, Monoclonal
650 0 4 _aHumans
650 0 4 _aIpilimumab
650 0 4 _aMelanoma
650 0 4 _aNivolumab
773 0 _tThe Lancet. Oncology
_gvol. 17
_gno. 11
_gp. 1471-1472
856 4 0 _uhttps://doi.org/10.1016/S1470-2045(16)30409-0
_zAvailable from publisher's website
999 _c26409398
_d26409398